



DEVELOPING COMMERCIAL OUTCOMES

CEO Presentation

Julie Phillips | CEO and Director, BioDiem Ltd



SAFE HARBOUR STATEMENT

This presentation is provided to you for information purposes only and should not be construed as investment advice or an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in Opal Biosciences Limited (“Opal”) or BioDiem Limited (“BioDiem”), or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in BioDiem or Opal will be entered into on the basis of this presentation.

This presentation contains forward-looking statements which are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, at the date this presentation was prepared, are expected to take place. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of BioDiem or Opal. BioDiem or Opal cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward looking statements contained in this presentation will actually occur and you should not place reliance on these forward looking statements.

To the maximum extent permitted by applicable laws, BioDiem or Opal and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of BioDiem or Opal .

FY2019 Highlights



Income from royalties and milestone payments totalling \$132,369



Successful capital raising into subsidiary Opal Biosciences Ltd - New data from BDM-I studies



LAIV marketing application lodged in China



Studies underway for new LAIV product in India

LAIV Influenza Vaccine Program



Changchun BCHT Biotechnology Co (China)

- Application for marketing lodged with National Medical Products Administration (Chinese FDA)
- Regulatory review underway

BioDiem entitled to receive royalties on the sales in the private sector in China.



LAIV Influenza Vaccine Program

BioDiem



SERUM INSTITUTE OF INDIA PVT. LTD.

Cyrus Poonawalla Group

- Clinical trials commenced for new LAIV product
- Liquid, quadrivalent vaccine

BioDiem receives royalties on the sales in the private sector in India.





Opal Biosciences Ltd

An early stage biotechnology company focused on the development of new treatments for drug-resistant or hard-to-treat infections.



Opal's drug, BDM-I, has shown in the laboratory that it can kill many serious human disease-causing microbes including six "Urgent Threats" identified by the US Centers of Disease Control and Prevention (CDC) in its latest Report ☆.



Board & Management



Board of Directors

Hugh Morgan AO <i>Chairman</i>	<i>A well-known Australian businessman with international and local advisory roles.</i>
Julie Phillips <i>Managing director</i>	<i>Multinational pharma background in regulatory affairs, health economics and clinical trials</i>
Ken Windle <i>Non-executive director</i>	<i>Former senior international positions at GSK including Head of Global Commercialisation.</i>
Peter Snowball <i>Non-executive director</i>	<i>Background in financial markets including Barclays, Merrill Lynch and J B Were.</i>

Advisor

Dr Jane Ryan	<i>PhD in Immunology and Biochemistry; Former Vice President (Global), Product Development and Strategic Marketing of Biota overseeing US\$231m HHS-BARDA contract. Engagement consultant CSIRO manufacturing and and NED Anantara Lifesciences</i>
--------------	---

FY19 Highlights



New priority
infection
target found:
Candida auris



New data
from animal
studies




Successful
capital
raisings



Inclusion in
CDC's
international call
for action:
Antimicrobial
Resistance (AMR)
Challenge



Financial markets
executive, Peter
Snowball, joined
the board



New
international
patent filing

FY19 Highlights cont'd



New priority infection target found: *Candida auris*

- New testing has found a disease threat which is new and serious and where, in the lab, BDM-I shows it works better than existing treatments.



New data from animal studies

- New studies have shown the amount of BDM-I that test animals can be given without side effects may be sufficient to kill disease-causing microbes

ANTIBIOTIC RESISTANCE THREATS
IN THE UNITED STATES

2019



*“antibiotic-resistant bacteria and fungi cause more than 2.8 million infections and 35,000 deaths in the US each year. **That means, on average, someone in the US gets an antibiotic-resistant infection every 11 seconds and every 15 minutes someone dies.**”*





Cash position

Opening cash position: FY2018

- \$422,395

Average monthly cash burn (excluding receipts):

- \$34,971

Receipts:

- \$252,750 capital raising
- \$53,469 received from R&D Tax Incentive
- \$27,500 received from Grant

Closing cash position: FY2019

- \$336,466

Post June 30

- \$280,000 raised from early exercise of options





Completion of regulatory review in China



**Continue to seek external interest
in LAIV technology licence**



Opal Biosciences:

- Continue BDM-I development
 - Grant funding
 - Application submitted Nov 2019
 - US agencies assistance
 - Ongoing
 - Feb 2020 option exercise to raise up to \$326K
- Aiming for outlicence or preparation for clinical trial



DEVELOPING COMMERCIAL OUTCOMES

AGM 2019

Julie Phillips | CEO and Director, BioDiem Ltd

